Akebia Therapeutics, Inc. (AKBA) Financials

AKBA Assets vs Liabilities

DateAssetsLiabilities
2024-03-31 225.5 million 252.7 million
2023-12-31 241.7 million 272.3 million
2023-09-30 235.0 million 274.4 million
2023-06-30 253.7 million 280.5 million

AKBA Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2024-03-31 -19.4 million 2.4 million
2023-12-31 -2.3 million 1.5 million
2023-09-30 -7.2 million 1.8 million
2023-06-30 3.6 million 3.5 million

AKBA Net Income

No data available :(

AKBA Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2024-03-31 42.0 million - 12.7 million
2023-12-31 42.9 million - 13.4 million
2023-09-30 46.5 million - 15.1 million
2023-06-30 53.6 million 19.2 million 16.2 million

AKBA Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2024-03-31 205.0 million
2023-12-31 190.5 million
2023-09-30 188.3 million
2023-06-30 186.8 million

AKBA Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2024-03-31 - 9.4 million 25.4 million -
2023-12-31 - 9.5 million 854000 25.4 million
2023-09-30 - 13.3 million 22.7 million 22.7 million
2023-06-30 - 20.2 million 27.0 million 27.0 million

AKBA Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2024-03-31 32.6 million 12.0 million
2023-12-31 56.2 million 19.1 million
2023-09-30 42.0 million 18.0 million
2023-06-30 56.4 million 17.3 million

AKBA

Price: $1.03

52 week price:
0.78
2.48

Earnings Per Share: -0.28 USD

P/E Ratio: -5.32

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 1.3 million

Ebitda: -24.0 million

Market Capitalization: 270.4 million

Links: